Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 4/20 | 0.90 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.90 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.90 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.90 |
| ▸ | DRD1 | P21728 | 3/20 | 0.90 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.90 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.90 |
| ▸ | HTR1A | P08908 | 2/20 | 0.90 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.90 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.90 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.90 |
| ▸ | DRD3 | P35462 | 2/20 | 0.90 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.90 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.90 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.90 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.90 |
| ▸ | HTR2C | P28335 | 2/20 | 0.90 |
| ▸ | HTR2B | P41595 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958564 | 1.00 | ABCB11 (0.90) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| Amlodipine SCHEMBL29397019 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| Levamlodipine SCHEMBL30994756 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| SCHEMBL29599419 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| SCHEMBL13097922 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| Amlodipine SCHEMBL29664887 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| Amlodipine SCHEMBL1816641 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| Levamlodipine SCHEMBL41283 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| Amlodipine SCHEMBL26478 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 | |
| Amlodipine SCHEMBL912531 | 0.95 | TBXA2R (1.00) | ABCB11TBXA2RADRA1ASLC6A3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039211-A | Method for synthesizing amlodipine EP impurity E and amlodipine EP impurity F | 深圳振强生物技术有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-113933414-B | Method for detecting organic impurities in amlodipine besylate composite preparation | 株洲千金药业股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-114814060-A | Detection method of valsartan amlodipine tablet related substances | 上海博志研新药物技术有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-119039211-A | Method for synthesizing amlodipine EP impurity E and amlodipine EP impurity F | 深圳振强生物技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119039211-A | Method for synthesizing amlodipine EP impurity E and amlodipine EP impurity F | 深圳振强生物技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119039211-A | Method for synthesizing amlodipine EP impurity E and amlodipine EP impurity F | 深圳振强生物技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118271201-A | With NMDA receptor-Ca2+Heterodiad compound with channel as target point, and preparation method and application thereof | 合肥工业大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-114814060-B | Detection method of valsartan amlodipine tablet related substances | 上海博志研新药物研究有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-113933414-B | Method for detecting organic impurities in amlodipine besylate composite preparation | 株洲千金药业股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-114814060-A | Detection method of valsartan amlodipine tablet related substances | 上海博志研新药物技术有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-113933414-A | Method for detecting organic impurities in irbesartan amlodipine besylate composite preparation | 株洲千金药业股份有限公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-7098211-B2 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1554267-A1 | DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY | Artesian Therapeutics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040242648-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004033444-A1 | DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY | ARTESIAN THERAPEUTICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033444-A1 | DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY | ARTESIAN THERAPEUTICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003101965-A1 | TWO CRYSTALLINE HYDRATE FORMS OF AMLODIPINE BENZENESULFONATE OF HIGH PURITY, PROCESSES FOR THEIR PREPARATION AND USE | LEK PHARMACEUTICALS D.D. (SI) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242648-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | CACNA1C, PDE3A, PDE3B | ABCB11 2526/4885TBXA2R 251/4885ADRA1A 1024/4885 |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | CACNA1C, PDE3A, PDE3B | ABCB11 2526/4885TBXA2R 251/4885ADRA1A 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.